ADMA Biologics, Inc.
ADMA
$9.37
-$0.17-1.78%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -19.13% | -20.03% | -25.67% | 207.41% | 500.55% |
| Total Depreciation and Amortization | -2.81% | 0.84% | 0.63% | -2.63% | -5.39% |
| Total Amortization of Deferred Charges | -8.65% | -19.14% | -24.61% | -48.32% | -56.77% |
| Total Other Non-Cash Items | 144.77% | 143.86% | 149.31% | -234.97% | -260.66% |
| Change in Net Operating Assets | 18.60% | -44.96% | -652.98% | -260.64% | -859.48% |
| Cash from Operations | 78.23% | 26.78% | -57.53% | -24.50% | 5.07% |
| Capital Expenditure | -85.18% | -92.98% | -174.43% | -263.76% | -71.76% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 574.84% | 284.14% | 295.99% | 79.33% | 69.66% |
| Cash from Investing | -30.65% | -35.07% | -155.29% | -236.91% | -61.01% |
| Total Debt Issued | 566.67% | -- | -- | -22.22% | -77.78% |
| Total Debt Repaid | 14.58% | -77.35% | -76.56% | 28.17% | 43.25% |
| Issuance of Common Stock | -82.62% | -47.14% | -60.18% | -57.54% | 316.62% |
| Repurchase of Common Stock | -1,830.33% | -1,643.37% | -734.58% | -608.33% | -174.91% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -127.64% | -455.27% | -455.27% | 64.23% | 89.06% |
| Cash from Financing | -20.32% | 26.50% | 24.49% | 0.51% | -57.40% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2,140.81% | 152.96% | -129.96% | -301.77% | -92.07% |